LEADS BIOLABS-B's Price Target Raised to HK$116.9 by CLSA, Outperform Rating Maintained

Deep News

Yesterday

CLSA has released a research report indicating that LEADS BIOLABS-B (09887) generated collaboration revenue of RMB 36 million in the first half of the year. The firm anticipates a key catalyst from updated data on LBL-024 for first-line treatment of non-small cell lung cancer (NSCLC), which is scheduled to be presented as an oral presentation at the 2026 World Conference on Lung Cancer (WCLC) later this month.

The company has guided that its Phase III clinical trial for LBL-024 in first-line NSCLC will commence in 2027 and has been actively seeking global partners since last month. Consequently, CLSA has raised its sales forecast for this year by 35.6% and adjusted its earnings projections for 2026 through 2028 (by -15%, -25.7%, and +14.6% respectively). The target price has been increased from HK$108 to HK$116.9, with an "Outperform" rating maintained.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1180112319"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180112319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180112319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180112319","market":"hk","top_or_hot":-1,"title":"LEADS BIOLABS-B's Price Target Raised to HK$116.9 by CLSA, Outperform Rating Maintained","media":"Deep News","content":"<p>CLSA has released a research report indicating that <b>LEADS BIOLABS-B (09887)</b> generated collaboration revenue of RMB 36 million in the first half of the year. The firm anticipates a key catalyst from updated data on LBL-024 for first-line treatment of non-small cell lung cancer (NSCLC), which is scheduled to be presented as an oral presentation at the 2026 World Conference on Lung Cancer (WCLC) later this month.<br><br>The company has guided that its Phase III clinical trial for LBL-024 in first-line NSCLC will commence in 2027 and has been actively seeking global partners since last month. Consequently, CLSA has raised its sales forecast for this year by 35.6% and adjusted its earnings projections for 2026 through 2028 (by -15%, -25.7%, and +14.6% respectively). The target price has been increased from HK$108 to HK$116.9, with an \"Outperform\" rating maintained.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B's Price Target Raised to HK$116.9 by CLSA, Outperform Rating Maintained</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B's Price Target Raised to HK$116.9 by CLSA, Outperform Rating Maintained\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-02 17:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLSA has released a research report indicating that <b>LEADS BIOLABS-B (09887)</b> generated collaboration revenue of RMB 36 million in the first half of the year. The firm anticipates a key catalyst from updated data on LBL-024 for first-line treatment of non-small cell lung cancer (NSCLC), which is scheduled to be presented as an oral presentation at the 2026 World Conference on Lung Cancer (WCLC) later this month.<br><br>The company has guided that its Phase III clinical trial for LBL-024 in first-line NSCLC will commence in 2027 and has been actively seeking global partners since last month. Consequently, CLSA has raised its sales forecast for this year by 35.6% and adjusted its earnings projections for 2026 through 2028 (by -15%, -25.7%, and +14.6% respectively). The target price has been increased from HK$108 to HK$116.9, with an \"Outperform\" rating maintained.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252160.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","start_time":0,"source_url":"","article_id":"1180112319","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180112319","pubTimestamp":1788340334,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CLSA has released a research report indicating that LEADS BIOLABS-B (09887) generated collaboration revenue of RMB 36 million in the first half of the year. The firm anticipates a key catalyst from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","EWH":"香港ETF-iShares MSCI","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","09887":"维立志博-B","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK1161":"生物科技"},"translate_title":"里昂证券将 LEADS BIOLABS-B 目标价上调至 116.9 港元，维持跑赢大盘评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWH":1,"09887":1},"content_text":"CLSA has released a research report indicating that LEADS BIOLABS-B (09887) generated collaboration revenue of RMB 36 million in the first half of the year. The firm anticipates a key catalyst from updated data on LBL-024 for first-line treatment of non-small cell lung cancer (NSCLC), which is scheduled to be presented as an oral presentation at the 2026 World Conference on Lung Cancer (WCLC) later this month.The company has guided that its Phase III clinical trial for LBL-024 in first-line NSCLC will commence in 2027 and has been actively seeking global partners since last month. Consequently, CLSA has raised its sales forecast for this year by 35.6% and adjusted its earnings projections for 2026 through 2028 (by -15%, -25.7%, and +14.6% respectively). The target price has been increased from HK$108 to HK$116.9, with an \"Outperform\" rating maintained.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}